Clinician describes new ultrasound-guided core biopsy technique
A medical team at the University of California (UC) Davis Health recently performed what it’s calling the world’s first endoscopic, ultrasound-guided core biopsy of a pancreatic tumor with a drilling method.
The team, led by Antonio Mendoza-Ladd, MD, said that this method successfully collected a larger-than-normal core of tumor tissue in an efficient manner. It highlighted that this can make way for better diagnostic workup.
“It is done in an easier-to-control way. We only need to do one puncture,” Mendoza-Ladd told AuntMinnie.com. “The cores we obtain with this device are better than regular needles.”
The ...
Source: AuntMinnie.com Headlines - February 26, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: Ultrasound Advanced Visualization Source Type: news
Low Rate of Aspiration With GLP-1s During Upper GI Endoscopy Low Rate of Aspiration With GLP-1s During Upper GI Endoscopy
A large retrospective review provided the first cumulative incidence rate of pulmonary aspiration in those undergoing upper endoscopy while receiving popular diabetes and obesity treatments.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - January 10, 2024 Category: Drugs & Pharmacology Tags: Gastroenterology Source Type: news
EndoSound gets FDA nod for EVS device
Medical technology developer EndoSound has received 510(k) clearance with breakthrough device designation from the U.S. Food and Drug Administration (FDA) for its EndoSound Vision System (EVS).The EVS is a new endoscopic ultrasound device that attaches to upper gastrointestinal endoscopes for access to imaging and therapeutic procedures. EndoSound, based in Portland, OR, said it expects the device to be used in settings like the ambulatory surgery center preferred by patients, providers, and payers. (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 2, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
Endoscopy Still an Option for Some 90-Year-Olds With GI Bleeds
(MedPage Today) -- VANCOUVER, British Columbia -- A significant proportion of very elderly people admitted for upper gastrointestinal bleeds underwent esophagogastroduodenoscopy (EGD), with mortality significantly higher in the oldest patients... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - October 26, 2023 Category: Gastroenterology Source Type: news
GI Endoscopy Can Lead to Work-Related Injuries
(MedPage Today) -- VANCOUVER, British Columbia -- More than half of gastrointestinal endoscopists reported that they have experienced musculoskeletal injuries related to their practice, researchers said here.
In a systematic review and meta... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 23, 2023 Category: American Health Source Type: news
Real-Time, Blood-Sensing Capsule Diagnoses UGIB in 7 Minutes Real-Time, Blood-Sensing Capsule Diagnoses UGIB in 7 Minutes
PillSense, a blood-sensing capsule, accurately detects upper gastrointestinal bleeding (UGIB) in around 7 minutes and promises to improve endoscopy workflow.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - October 16, 2023 Category: Surgery Tags: Gastroenterology News Source Type: news
What Causes Dysphagia?
Discussion
Swallowing is a complex process with 4 phases:
Preparatory – food is moistened with saliva, chewed and prepared into a bolus by teeth, tongue and hard palate.
Oral – food bolus is moved into oropharynx by tongue and triggers the swallow reflex. Soft palate elevates to prevent nasopharyngeal reflux.
Pharyngeal – food bolus is moved through the oropharynx and hypopharynx to the esophagus. Respiration stops briefly with vocal fold adduction and larynx elevation to prevent aspiration.
Esophageal – the cricopharyngeaul muscle relaxes which allows the food bolus into the esophagus where it is ...
Source: PediatricEducation.org - October 16, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Esketamine for Sedation Among Patients Undergoing GI Endoscopy Esketamine for Sedation Among Patients Undergoing GI Endoscopy
This review aimed to assess the efficacy and safety of esketamine as an adjunct to propofol for sedation during endoscopic procedures.BMC Anesthesiology (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - August 17, 2023 Category: Surgery Tags: Gastroenterology Journal Article Source Type: news
UHC Ditches Prior Authorization in Favor of New Policy UHC Ditches Prior Authorization in Favor of New Policy
The giant health insurer has shelved the controversial prior authorization policy for GI endoscopy procedures. In its place is an ' advance notification program. 'Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - June 1, 2023 Category: Gastroenterology Tags: Gastroenterology News Alert Source Type: news
First Phase 3 TREMFYA ® (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction Results Among Patients with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, May 9, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new efficacy and safety data from the Phase 3 QUASAR Induction Study evaluating the investigational use of TREMFYA® (guselkumab) in adults with moderately to severely active ulcerative colitis (UC)a who had an inadequate response or intolerance to conventionalb and/or advanced therapies.1,c The data show statistically significant and clinically meaningful improvements across symptomatic and histo-endoscopic outcome measures.1 Safety data were also consistent with the known safety profile of TREMFYA in ...
Source: Johnson and Johnson - May 9, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Butorphanol for Visceral Pain in GI Endoscopy Butorphanol for Visceral Pain in GI Endoscopy
Might adding butorphanol to propofol decrease the incidence of postoperative visceral pain in patients undergoing gastroscopy and colonoscopy?BMC Anesthesiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 4, 2023 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news
New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
TREMFYA ® (guselkumab) Demonstrates a Differentiated Binding Mechanism from Risankizumab in In Vitro Studies
SPRING HOUSE, PENNSYLVANIA, March 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced additional results from in vitro MODIF-Y studies, which continue to support a hypothesis that not all IL-23 inhibitors are the same by demonstrating a differentiated binding mechanism for TREMFYA® (guselkumab) from risankizumab. Findings show that guselkumab is able to dose-dependently bind to CD64+a myeloid cells,1 the predominant source of IL-23-driven inflammation in the gut.2,b Data comprise one of Janssen’s 22 oral and poster presentations at the 18th Congress of the European Crohn’s and Col...
Source: Johnson and Johnson - March 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
New TREMFYA ® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2b QUASAR Induction Study 1 in adults with moderately to severely active ulcerative colitis (UC) with inadequate responses to previous treatments. The data presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting show an overall clinical response rate of approximately 80 percent in patients who were randomized to TREMFYA® (guselkumab).Clinical responsea at weeks 12 or 24 of the study was ultimately achieved by 80.2 percent of patients who w...
Source: Johnson and Johnson - October 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
